tbuckley/cabot-search huggingface dataset:
Balancing Quality and Quantity in Optimizing Health Care Resource Utilization
Authors: Leigh Ann O’Banion, Karen Woo
Journal: JAMA Network Open (2021)

David P. Stonko, MD, MS; Chen Dun, MHS; Christi Walsh, MSN, CRNP; Marlin Schul, MD, MBA; John Blebea, MD; Edward M. Boyle, MD; Martin A. Makary, MD, MPH; Caitlin W. Hicks, MD, MS
Cardio-Oncology in Iran
Authors: Azin Alizadehasl, Feridoun Noohi, Majid Maleki, Mohammad Mehdi Peyghambari, Niloufar Akbari Parsa, Amir Hossein Emami, Asadollah Moosavi, Mehrdad Hagh Azali, Hamidreza Pouraliakbar, Payam Azadeh
Journal: JACC CardioOncology (2021)
NIH Diversity Supplement Awards by Year and Administering Institute
Authors: Katherine A. Hill, Mayur M. Desai, Sarwat I. Chaudhry, Mytien Nguyen, Dowin Boatright
Journal: JAMA (2021)

This study charts the use of the National Institutes of Health’s diversity supplements, grant enhancement awards designed to provide research opportunities to individuals from underrepresented racial or ethnic groups, since the program’s inception in 1989.
The iPSC perspective on schizophrenia
Authors: Noora Räsänen, Jari Tiihonen, Marja Koskuvi, Šárka Lehtonen, Jari Koistinaho
Journal: Trends in Neurosciences (2021)

Over a decade of schizophrenia research using human induced pluripotent stem cell (iPSC)-derived neural models has provided substantial data describing neurobiological characteristics of the disorder in vitro. Simultaneously, translation of the results into general mechanistic concepts underlying schizophrenia pathophysiology has been trailing behind. Given that modeling brain function using cell cultures is challenging, the gap between the in vitro models and schizophrenia as a clinical disorder has remained wide. In this review, we highlight reproducible findings and emerging trends in recent schizophrenia-related iPSC studies. We illuminate the relevance of the results in the context of human brain development, with a focus on processes coinciding with critical developmental periods for schizophrenia.
Error in Article Information
Journal: JAMA Network Open (2021)

Xingzhe Li, MD, MPH; Sarin Kitpanit, MD; Anna Lee, MD, MPH; Dennis Mah, PhD; Kevin Sine, BS; Eric J. Sherman, MD; Lara A. Dunn, MD; Loren S. Michel, MD; James Fetten, MD; Kaveh Zakeri, MD, MAS; Yao Yu, MD; Linda Chen, MD; Jung Julie Kang, MD, PhD; Daphna Y. Gelblum, MD; Sean M. McBride, MD, MPH; Chiaojung J. Tsai, MD, PhD; Nadeem Riaz, MD; Nancy Y. Lee, MD
A conductive supramolecular hydrogel creates ideal endogenous niches to promote spinal cord injury repair
Authors: Biao Yang, Chengzhen Liang, Di Chen, Feng Cheng, Yuang Zhang, Shaoke Wang, Jiawei Shu, Xianpeng Huang, Jingkai Wang, Kaishun Xia, Liwei Ying, Kesi Shi, Chenggui Wang, Xuhua Wang, Fangcai Li, Qian Zhao, Qixin Chen
Journal: Bioactive Materials (2021)

The current effective method for treatment of spinal cord injury (SCI) is to reconstruct the biological microenvironment by filling the injured cavity area and increasing neuronal differentiation of neural stem cells (NSCs) to repair SCI. However, the method is characterized by several challenges including irregular wounds, and mechanical and electrical mismatch of the material-tissue interface. In the current study, a unique and facile agarose/gelatin/polypyrrole (Aga/Gel/PPy, AGP3) hydrogel with similar conductivity and modulus as the spinal cord was developed by altering the concentration of Aga and PPy. The gelation occurred through non-covalent interactions, and the physically crosslinked features made the AGP3 hydrogels injectable. In vitro cultures showed that AGP3 hydrogel exhibited excellent biocompatibility, and promoted differentiation of NSCs toward neurons whereas it inhibited over-proliferation of astrocytes. The in vivo implanted AGP3 hydrogel completely covered the tissue defects and reduced injured cavity areas. In vivo studies further showed that the AGP3 hydrogel provided a biocompatible microenvironment for promoting endogenous neurogenesis rather than glial fibrosis formation, resulting in significant functional recovery. RNA sequencing analysis further indicated that AGP3 hydrogel significantly modulated expression of neurogenesis-related genes through intracellular Ca2+ signaling cascades. Overall, this supramolecular strategy produces AGP3 hydrogel that can be used as favorable biomaterials for SCI repair by filling the cavity and imitating the physiological properties of the spinal cord.
Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathways
Authors: Kalyani Patil, Shilpa Kuttikrishnan, Abdul Q. Khan, Fareed Ahmad, Majid Alam, Joerg Buddenkotte, Aamir Ahmad, Martin Steinhoff, Shahab Uddin
Journal: Seminars in Cancer Biology (2021)

Cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of lymphoproliferative neoplasms that exhibit a wide spectrum of immune-phenotypical, clinical, and histopathological features. The biology of CTCL is complex and remains elusive. In recent years, the application of next-generation sequencing (NGS) has evolved our understanding of the pathogenetic mechanisms, including genetic aberrations and epigenetic abnormalities that shape the mutational landscape of CTCL and represent one of the important pro-tumorigenic principles in CTCL initiation and progression. Still, identification of the major pathophysiological pathways including genetic and epigenetic components that mediate malignant clonal T cell expansion has not been achieved. This is of prime importance given the role of malignant T cell clones in fostering T helper 2 (Th2)-bias tumor microenvironment and fueling progressive immune dysregulation and tumor cell growth in CTCL patients, manifested by the secretion of Th2-associated cytokines and chemokines. Alterations in malignant cytokine and chemokine expression patterns orchestrate the inflammatory milieu and influence the migration dynamics of malignant clonal T cells. Here, we highlight recent insights about the molecular mechanisms of CTCL pathogenesis, emphasizing the role of cytokines, chemokines, and associated downstream signaling networks in driving immune defects, malignant transformation, and disease progression. In-depth characterization of the CTCL immunophenotype and tumoral microenvironment offers a facile opportunity to expand the therapeutic armamentarium of CTCL, an intractable malignant skin disease with poor prognosis and in dire need of curative treatment approaches.
Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial
Authors: Alberto C S Costa, Ana C Brandão, Richard Boada, Veridiana L Barrionuevo, Hudson G Taylor, Elizabeth Roth, Melissa R Stasko, Mark W Johnson, Fernanda F Assir, Maria P Roberto, Patrícia Salmona, Guilherme Abreu-Silveira, Ilya Bederman, Erin Prendergast, Anke Hüls, Sarina Abrishamcar, Zan Mustacchi, Thomas Scheidemantel, Nancy J Roizen, Stephen Ruedrich
Journal: The Lancet Neurology (2021)
Omitted Affiliation
Authors: Manyoo Agarwal, Gregg Fonarow, Boback Ziaeian
Journal: JAMA Cardiology (2021)

Sean P. Collins, MD, MSc; Dandan Liu, PhD; Cathy A. Jenkins, MSc; Alan B. Storrow, MD; Phillip D. Levy, MD, MPH; Peter S. Pang, MD; Anna Marie Chang, MD; Douglas Char, MD; Deborah J. Diercks, MD; Gregory J. Fermann, MD; Jin H. Han, MD; Brian Hiestand, MD, MPH; Christopher Hogan, MD; Christina J. Kampe, MAcc; Yosef Khan, MD, PhD, MPH; Sangil Lee, MD; JoAnn Lindenfeld, MD; Jennifer Martindale, MD; Candace D. McNaughton, MD, PhD; Karen F. Miller, RN, BSN; Carolyn Miller-Reilly, PhD, RN; Kelly Moser, BA; W. Frank Peacock, MD; Chad Robichaux, MPH; Russell Rothman, MD, MPH; Jon Schrock, MD; Wesley H. Self, MD, MPH; Adam J. Singer, MD; Sarah A. Sterling, MD; Michael J. Ward, MD, PhD; Cheryl Walsh; Javed Butler, MD, MPH, MBA
Polypharmacologic Reprogramming of Tumor-Associated Macrophages toward an Inflammatory Phenotype
Authors: Nao Nishida-Aoki, Taranjit S. Gujral
Journal: Cancer Research (2021)

Tumor-associated macrophages (TAM) are an important component of the tumor microenvironment (TME) that can promote tumor progression, metastasis, and resistance to therapies. Although TAMs represent a promising target for therapeutic intervention, the complexity of the TME has made the study of TAMs challenging. Here, we established a physiologically relevant in vitro TAM polarization system that recapitulates TAM protumoral activities. This system was used to characterize dynamic changes in gene expression and protein phosphorylation during TAM polarization and to screen phenotypic kinase inhibitors that impact TAM programming. BMS-794833, a multitargeted compound, was identified as a potent inhibitor of TAM polarization. BMS-794833 decreased protumoral properties of TAMs in vitro and suppressed tumor growth in mouse triple-negative breast cancer models. The effect of BMS-794833 was independent of its primary targets (MET and VEGFR2) but was dependent on its effect on multiple signaling pathways, including focal adhesion kinases, SRC family kinases, STAT3, and p38 MAPKs. Collectively, these findings underline the efficacy of polypharmacologic strategies in reprogramming complex signaling cascades activated during TAM polarization. SIGNIFICANCE: A physiologically relevant in vitro system of TAM polarization uncovers signaling pathways that regulate polarization and identifies strategies to target macrophage reprogramming to suppress cancer growth.
“Recent gains reversed, targets off track”
Authors: None The Lancet Microbe
Journal: The Lancet Microbe (2021)

In The Lancet Microbe's October 2021 editorial, we pondered on the effects of the COVID-19 pandemic on the fights against three other major infectious diseases—tuberculosis, malaria, and HIV—and wondered whether the tuberculosis response, in particular, was another of its casualties. The WHO Global Tuberculosis Report 2021, published on Oct 14, provided a grim, affirmative answer to our question, with our title quote a refrain throughout the document and an apt overall summary of the main findings.
Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function
Authors: Huaishan Wang, Hui Chen, Shujing Liu, Jie Zhang, Hezhe Lu, Rajasekharan Somasundaram, Robin Choi, Gao Zhang, Lingling Ou, John Scholler, Shifu Tian, Liyun Dong, Guo Yeye, Lili Huang, Thomas Connelly, Ling Li, Alexander Huang, Tara C Mitchell, Yi Fan, Carl H June, Gordon B Mills, Wei Guo, Meenhard Herlyn, Xiaowei Xu
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Gamma delta (γδ) T cells are attractive effector cells for cancer immunotherapy. Vδ2 T cells expanded by zoledronic acid (ZOL) are the most commonly used γδ T cells for adoptive cell therapy. However, adoptive transfer of the expanded Vδ2 T cells has limited clinical efficacy. Methods We developed a costimulation method for expansion of Vδ2 T cells in PBMCs by activating γδ T-cell receptor (γδTCR) and Toll-like receptor (TLR) 7/8 using isopentenyl pyrophosphate (IPP) and resiquimod, respectively, and tested the functional markers and antitumoral effects in vitro two-dimensional two-dimensional and three-dimensional spheroid models and in vivo models. Single-cell sequencing dataset analysis and reverse-phase protein array were employed for mechanistic studies. Results We find that Vδ2 T cells expanded by IPP plus resiquimod showed significantly increased cytotoxicity to tumor cells with lower programmed cell death protein 1 (PD-1) expression than Vδ2 T cells expanded by IPP or ZOL. Mechanistically, the costimulation enhanced the activation of the phosphatidylinositol 3-kinase (PI3K)–protein kinase B (PKB/Akt)–the mammalian target of rapamycin (mTOR) pathway and the TLR7/8–MyD88 pathway. Resiquimod stimulated Vδ2 T-cell expansion in both antigen presenting cell dependent and independent manners. In addition, resiquimod decreased the number of adherent inhibitory antigen-presenting cells (APCs) and suppressed the inhibitory function of APCs by decreasing PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) expression in these cells during in vitro Vδ2 T-cell expansion. Finally, we showed that human Vδ2 T cells can be expanded from PBMCs and spleen of humanized NSG mice using IPP plus resiquimod or ZOL, demonstrating that humanized mice are a promising preclinical model for studying human γδ T-cell development and function. Conclusions Vδ2 T cells expanded by IPP and resiquimod demonstrate improved anti-tumor function and have the potential to increase the efficacy of γδ T cell-based therapies.
Efficacy and Safety of 4 Fractions of Carbon-Ion Radiation Therapy for Hepatocellular Carcinoma: A Prospective Study
Authors: Kei Shibuya, Hiroyuki Katoh, Yoshinori Koyama, Shintaro Shiba, Masahiko Okamoto, Shohei Okazaki, Kenichiro Araki, Satoru Kakizaki, Ken Shirabe, Tatsuya Ohno
Journal: Liver Cancer (2021)

Prospective evidence supporting the safety and efficacy of carbon-ion radiotherapy (C-ion RT) for hepatocellular carcinoma (HCC) remains lacking. This prospective study aimed to evaluate the safety and efficacy of hypofractionated C-ion RT in patients with HCC.The inclusion criteria were as follows: (1) pathologically or clinically diagnosed HCC; (2) measurable tumor and tumor size ≤10 cm; (3) absence of major vascular invasion; (4) no extrahepatic metastasis; (5) the alimentary tract was not adjacent to the target lesion (>1 cm); (6) not suitable for or refusal to undergo surgery or local ablative therapies; (7) an interval ≥4 weeks from previous therapy; (8) no other intrahepatic lesion or at least 2 years after the previous curative therapy; (9) performance status score, 0-2; and (10) Child-Pugh score, 5-9. The prescribed C-ion RT dose was 52.8 Gy (relative biological effectiveness [RBE]) or 60.0 Gy (RBE) in 4 fractions.In total, 35 patients with HCC were enrolled between October 2010 and May 2016. The median follow-up durations in the survivor group (n = 23) and in the whole cohort were 55.1 and 49.0 months, respectively. The 2-, 3-, and 4-year overall survival rates were 82.8%, 76.7%, and 69.4%, respectively. The 2-, 3-, and 4-year local control (LC) rates were 92.6%, 76.5%, and 76.5%, respectively. The median time-to-progression was 25.6 months (95% confidence interval, 13.7-37.5 months). Grade 4 or 5 toxicities were not observed. Grade 3 acute and late toxicities were observed in 2 patients. There was no significant deterioration in serum albumin, bilirubin, prothrombin time-international normalized ratio, platelet count, or Child-Pugh score after C-ion RT.Four fractions of C-ion RT for HCC did not yield serious adverse events and showed promising LC, thus making it a safe and effective modality for this type of malignancy.
Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years
Authors: Fernando Magro, Diogo Magalhães, Marta Patita, Bruno Arroja, Paula Lago, Isadora Rosa, Helena Tavares de Sousa, Paula Ministro, Irinia Mocanu, Ana Vieira, Joana Castela, Joana Moleiro, Joana Roseira, Eugénia Cancela, Paula Sousa, Francisco Portela, Luís Correia, Mafalda Santiago, Sandra Dias, Catarina Alves, Joana Afonso, Silvio Danese, Laurent Peyrin-Biroulet, Claudia Camila Dias
Journal: Clinical Gastroenterology and Hepatology (2021)
The Future of Cardiac Magnetic Resonance Clinical Trials
Authors: Mark G. Rabbat, Raymond Y. Kwong, John F. Heitner, Alistair A. Young, Sujata M. Shanbhag, Steffen E. Petersen, Joseph B. Selvanayagam, Colin Berry, Eike Nagel, Bobak Heydari, Alicia M. Maceira, Chetan Shenoy, Christopher Dyke, Kenneth C. Bilchick
Journal: JACC. Cardiovascular imaging (2021)
Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance
Authors: Hannah N Bell, Ryan J Rebernick, Joshua Goyert, Rashi Singhal, Miljan Kuljanin, Samuel A Kerk, Wesley Huang, Nupur K Das, Anthony Andren, Sumeet Solanki, Shannon L Miller, Peter K Todd, Eric R Fearon, Costas A Lyssiotis, Steven P Gygi, Joseph D Mancias, Yatrik M Shah
Journal: Cancer Cell (2021)
A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era
Authors: Stefan M. Pfister, Miguel Reyes-Múgica, John K.C. Chan, Henrik Hasle, Alexander J. Lazar, Sabrina Rossi, Andrea Ferrari, Jason A. Jarzembowski, Kathy Pritchard-Jones, D. Ashley Hill, Thomas S. Jacques, Pieter Wesseling, Dolores H. López Terrada, Andreas von Deimling, Christian P. Kratz, Ian A. Cree, Rita Alaggio
Journal: Cancer Discovery (2021)

Abstract Pediatric tumors are uncommon, yet are the leading cause of cancer-related death in childhood. Tumor types, molecular characteristics, and pathogenesis are unique, often originating from a single genetic driver event. The specific diagnostic challenges of childhood tumors led to the development of the first World Health Organization (WHO) Classification of Pediatric Tumors. The classification is rooted in a multilayered approach, incorporating morphology, IHC, and molecular characteristics. The volume is organized according to organ sites and provides a single, state-of-the-art compendium of pediatric tumor types. A special emphasis was placed on “blastomas,” which variably recapitulate the morphologic maturation of organs from which they originate. Significance: In this review, we briefly summarize the main features and updates of each chapter of the inaugural WHO Classification of Pediatric Tumors, including its rapid transition from a mostly microscopic into a molecularly driven classification systematically taking recent discoveries in pediatric tumor genomics into account.
Intermittent Fasting and Obesity-Related Health Outcomes
Authors: Chanthawat Patikorn, Kiera Roubal, Sajesh K. Veettil, Viji Chandran, Tuan Pham, Yeong Yeh Lee, Edward L. Giovannucci, Krista A. Varady, Nathorn Chaiyakunapruk
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Several meta-analyses of randomized clinical trials (RCTs) have demonstrated the many health benefits of intermittent fasting (IF). However, there has been little synthesis of the strength and quality of this evidence in aggregate to date. <h3>Objective</h3> To grade the evidence from published meta-analyses of RCTs that assessed the associations of IF (zero-calorie alternate-day fasting, modified alternate-day fasting, the 5:2 diet, and time-restricted eating) with obesity-related health outcomes. <h3>Evidence Review</h3> PubMed, Embase, and Cochrane database of systematic reviews were searched from database inception to January 12, 2021. Data analysis was conducted from April 2021 through July 2021. Meta-analyses of RCTs investigating effects of IF in adults were included. The effect sizes of IF were recalculated using a random-effects model. We assessed the quality of evidence per association by applying the GRADE criteria (Grading of Recommendations, Assessment, Development, and Evaluations) as high, moderate, low, and very low. <h3>Findings</h3> A total of 11 meta-analyses comprising 130 RCTs (median [IQR] sample size, 38 [24-69] participants; median [IQR] follow-up period, 3 [2-5] months) were included describing 104 unique associations of different types of IF with obesity-related health outcomes (median [IQR] studies per association, 4 [3-5]). There were 28 statistically significant associations (27%) that demonstrated the beneficial outcomes for body mass index, body weight, fat mass, low-density lipoprotein cholesterol, total cholesterol, triglycerides, fasting plasma glucose, fasting insulin, homeostatic model assessment of insulin resistance, and blood pressure. IF was found to be associated with reduced fat-free mass. One significant association (1%) supported by high-quality evidence was modified alternate-day fasting for 1 to 2 months, which was associated with moderate reduction in body mass index in healthy adults and adults with overweight, obesity, or nonalcoholic fatty liver disease compared with regular diet. Six associations (6%) were supported by moderate quality evidence. The remaining associations found to be significant were supported by very low (75 associations [72%]) to low (22 associations [21%]) quality evidence. <h3>Conclusions and Relevance</h3> In this umbrella review, we found beneficial associations of IF with anthropometric and cardiometabolic outcomes supported by moderate to high quality of evidence, which supports the role of IF, especially modified alternate-day fasting, as a weight loss approach for adults with overweight or obesity. More clinical trials with long-term follow-up are needed to investigate the effects of IF on clinical outcomes such as cardiovascular events and mortality.
IMI European Lead Factory — democratizing access to high-throughput screening
Authors: Philip S. Jones, Sylviane Boucharens, Stuart P. McElroy, Angus Morrison, Saman Honarnejad, Stan van Boeckel, Helma van den Hurk, Daniel Basting, Jörg Hüser, Stefan Jaroch, Eckhard Ottow, Jorg Benningshof, Rutger H. A. Folmer, Frank Leemhuis, Patricia M. Kramer-Verhulst, Vera J. M. Nies, Kristina M. Orrling, Ton Rijnders, Claudia Pfander, Ola Engkvist, Garry Pairaudeau, Peter B. Simpson, Jean-Yves Ortholand, Didier Roche, Alexander Dömling, Sven M. Kühnert, Peter W. M. Roevens, Herman van Vlijmen, Eva J. A. van Wanrooij, Christophe Verbruggen, Peter Nussbaumer, Huib Ovaa, Mario van der Stelt, Klaus Baek Simonsen, Lena Tagmose, Herbert Waldmann, James Duffy, Dirk Finsinger, Mirek Jurzak, Nicola A. Burgess-Brown, Wen H. Lee, Floris P. J. T. Rutjes, Hubert Haag, Christopher Kallus, Hartmut Mors, Thierry Dorval, Brigitte Lesur, Fernando Ramon Olayo, Daniel Hamza, Geraint Jones, Christopher Pearce, Alexander Piechot, Dimitrios Tzalis, Mads H. Clausen, Jeremy Davis, Daphné Derouane, Céline Vermeiren, Markus Kaiser, Robert A. Stockman, Denise V. Barrault, Andrew D. Pannifer, Jason R. Swedlow, Adam S. Nelson, Romano V. A. Orru, Eelco Ruijter, Steven P. van Helden, Volkhart M. Li, Ton Vries, Jon S. B. de Vlieger
Journal: Nature Reviews Drug Discovery (2021)
Deviated and early unsustainable stunted development of gut microbiota in children with autism spectrum disorder
Authors: Mingxing Lou, Aihua Cao, Cuiyuan Jin, Kai Mi, Xiyue Xiong, Zhaoyang Zeng, Xu Pan, Jinlong Qie, Shangfeng Qiu, Yaofang Niu, Hao Liang, Yanping Liu, Lin Chen, Zhi Liu, Qing Zhao, Xiyan Qiu, Yuanxiang Jin, Xiaoqi Sheng, Zhibin Hu, Gulei Jin, Jingshi Liu, Xingyin Liu, Yichao Wang
Journal: Gut (2021)

Recent studies have provided insights into the gut microbiota in autism spectrum disorder (ASD); however, these studies were restricted owing to limited sampling at the unitary stage of childhood. Herein, we aimed to reveal developmental characteristics of gut microbiota in a large cohort of subjects with ASD combined with interindividual factors impacting gut microbiota.
An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD
Authors: Grace En Hui Lim, Ansel Tang, Cheng Han Ng, Yip Han Chin, Wen Hui Lim, Darren Jun Hao Tan, Jie Ning Yong, Jieling Xiao, Chloe Wen-Min Lee, Mark Chan, Nicholas WS. Chew, Eunice Xiang Xuan Tan, Mohammad Shadab Siddiqui, Daniel Huang, Mazen Noureddin, Arun J. Sanyal, Mark D. Muthiah
Journal: Clinical Gastroenterology and Hepatology (2021)
Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study
Authors: Helen Campbell, Nick Andrews, Sydel R Parikh, Joanne White, Michael Edelstein, Xilian Bai, Jay Lucidarme, Ray Borrow, Mary E Ramsay, Shamez N Ladhani
Journal: The Lancet Child & Adolescent Health (2021)